Brian A. McCool

Brian A. McCool

Auto-generated profile, based on publicly available information

Brian A. McCool

Department of Translational Neuroscience, Wake Forest University School of Medicine, Winston-Salem, NC, 27157, United States

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 1997 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
PLParul P. Lakhlani
Parul P. Lakhlani
LMLeigh B. MacMillan
Leigh B. MacMillan
TGTian Zhi Guo
Tian Zhi Guo
BMBrian A. McCool
Brian A. McCool
DLDavid M. Lovinger
David M. Lovinger
LLLee E. Limbird
Lee E. Limbird
Norepinephrine contributes to antinociceptive, sedative, and sympatholytic responses in vivo , and α 2 adrenergic receptor (α 2 AR) agonists are used clinically to mimic these effects. Lack of subtype-specific agonists has prevented elucidation of the role that each α 2 AR subtype (α 2A , α 2B , and α 2C ) plays in these central effects. Here we demonstrate that α 2 AR agonist-elicited sedative, anesthetic-sparing, and analgesic responses are lost in a mouse line expressing a subtly mutated α 2A AR, D79N α 2A AR, created by two-step homologous recombination. These functional changes are accompanied by failure of the D79N α 2A AR to inhibit voltage-gated Ca 2+ currents and spontaneous neuronal firing, a measure of K + current activation. These results provide definitive evidence that the α 2A AR subtype is the primary mediator of clinically important central actions of α 2 AR agonists and suggest that the D79N α 2A AR mouse may serve as a model for exploring other possible α 2A AR functions in vivo .

30 September 2003 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
KVKent Vrana
Kent Vrana
JHJason D. Hipp
Jason D. Hipp
AGAshley M. Goss
Ashley M. Goss
BMBrian A. McCool
Brian A. McCool
DRDavid R. Riddle
David R. Riddle
JCJose B. Cibelli
Jose B. Cibelli
Parthenogenesis is the biological phenomenon by which embryonic development is initiated without male contribution. Whereas parthenogenesis is a common mode of reproduction in lower organisms, the mammalian parthenote fails to produce a successful pregnancy. We herein describein vitroparthenogenetic development of monkey (Macaca fascicularis) eggs to the blastocyst stage, and their use to create a pluripotent line of stem cells. These monkey stem cells (Cyno-1 cells) are positive for telomerase activity and are immunoreactive for alkaline phosphatase, octamer-binding transcription factor 4 (Oct-4), stage-specific embryonic antigen 4 (SSEA-4), tumor rejection antigen 1-60 (TRA 1-60), and tumor rejection antigen 1-81 (TRA 1-81) (traditional markers of human embryonic stem cells). They have a normal chromosome karyotype (40 + 2) and can be maintainedin vitroin an undifferentiated state for extended periods of time. Cyno-1 cells can be differentiatedin vitrointo dopaminergic and serotonergic neurons, contractile cardiomyocyte-like cells, smooth muscle, ciliated epithelia, and adipocytes. When Cyno-1 cells were injected into severe combined immunodeficient mice, teratomas with derivatives from all three embryonic germ layers were obtained. When grown on fibronectin/laminin-coated plates and in neural progenitor medium, Cyno-1 cells assume a neural precursor phenotype (immunoreactive for nestin). However, these cells remain proliferative and express no functional ion channels. When transferred to differentiation conditions, the nestin-positive precursors assume neuronal and epithelial morphologies. Over time, these cells acquire electrophysiological characteristics of functional neurons (appearance of tetrodotoxin-sensitive, voltage-dependent sodium channels). These results suggest that stem cells derived from the parthenogenetically activated nonhuman primate egg provide a potential source for autologous cell therapy in the female and bypass the need for creating a competent embryo.

1 December 2007 in Journal of Neurophysiology
Verified
Journal Article
Closed access
PDF file
ALAnna K. Läck
Anna K. Läck
MDMarvin Diaz
Marvin Diaz
ACAnn Chappell
Ann Chappell
DDDustin W. DuBois
Dustin W. DuBois
BMBrian A. McCool
Brian A. McCool
Withdrawal anxiety is a significant factor contributing to continued alcohol abuse in alcoholics. This anxiety is long-lasting, can manifest well after the overt physical symptoms of withdrawal, and is frequently associated with relapse in recovering alcoholics. The neurobiological mechanisms governing these withdrawal-associated increases in anxiety are currently unknown. The basolateral amygdala (BLA) is a major emotional center in the brain and regulates the expression of both learned fear and anxiety. Neurotransmitter system alterations within this brain region may therefore contribute to withdrawal-associated anxiety. Because evidence suggests that glutamate-gated neurotransmitter receptors are sensitive to acute ethanol exposure, we examined the effect of chronic intermittent ethanol (CIE) and withdrawal (WD) on glutamatergic synaptic transmission in the BLA. We found that slices prepared from CIE and WD animals had significantly increased contributions by synaptic NMDA receptors. In addition, CIE increased the amplitude of AMPA-receptor–mediated spontaneous excitatory postsynaptic currents (sEPSCs), whereas only WD altered the amplitude and kinetics of tetrodotoxin-resistant spontaneous events (mEPSCs). Similarly, the frequency of sEPSCs was increased in both CIE and WD neurons, although only WD increased the frequency of mEPSCs. These data suggest that CIE and WD differentially alter both pre- and postsynaptic properties of BLA glutamatergic synapses. Finally, we show that microinjection of the AMPA-receptor antagonist, DNQX, can attenuate withdrawal-related anxiety-like behavior. Together, our results suggest that increased glutamatergic function may contribute to anxiety expressed during withdrawal from chronic ethanol.

22 January 2009 in Alcohol, Clinical and Experimental Research
Verified
Journal Article
Closed access
PDF file
BMBrian A. McCool
Brian A. McCool
ACAnn M. Chappell
Ann M. Chappell

24 August 2012 in Alcohol, Clinical and Experimental Research
Verified
Journal Article
Closed access
PDF file
ACAnn M. Chappell
Ann M. Chappell
ECEugenia Carter
Eugenia Carter
BMBrian A. McCool
Brian A. McCool
JWJeff L. Weiner
Jeff L. Weiner

1 May 1995 in Neuron
Verified
Journal Article
Closed access
SIStephen R Ikeda
Stephen R Ikeda
DLDavid M Lovinger
David M Lovinger
BMBrian A McCool
Brian A McCool
DLDeborah L Lewis
Deborah L Lewis